20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Mirum Pharmaceuticals Inc (MIRM) operates in the BIOTECHNOLOGY industry and is headquartered in Foster City, United States with about 433 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, MIRM reported $521M in revenue and ($23M) in net income.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Interactive charts & full statements → Open the MIRM valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $618M | $521M | $337M | $186M | $77M | $19M | $11M | $0M | $0M |
| Gross Profit | $505M | $421M | $255M | $139M | $65M | $17M | ($1M) | $0M | $0M |
| Gross Margin % | 81.7% | 80.7% | 75.8% | 74.8% | 83.9% | 90.1% | -5.7% | — | — |
| Operating Income (EBIT) | ($108M) | ($22M) | ($88M) | ($109M) | ($131M) | ($173M) | ($104M) | ($55M) | ($3M) |
| Operating Margin % | -17.5% | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | -948.2% | — | — |
| Net Income | ($860M) | ($23M) | ($88M) | ($163M) | ($136M) | ($84M) | ($103M) | ($53M) | ($17M) |
| Net Margin % | -139.2% | -4.5% | -26.1% | -87.7% | -176.0% | -438.8% | -938.8% | — | — |
| EBITDA | ($776M) | $17M | ($49M) | ($136M) | ($123M) | ($65M) | ($102M) | ($54M) | ($17M) |
| Earnings Per Share (EPS) | $-14.55 | $-0.47 | $-1.85 | $-4.00 | $-3.99 | $-2.77 | $-4.09 | $-2.29 | $-0.75 |
| Shares Outstanding (M) | 63M | 50M | 48M | 41M | 34M | 30M | 25M | 23M | 23M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $176M | $160M | $149M | $133M | $128M | $112M | $99M | $90M |
| Gross Profit | $146M | $131M | $121M | $107M | $104M | $89M | $77M | $70M |
| Gross Margin % | 82.8% | 81.9% | 81.0% | 80.8% | 81.7% | 79.4% | 77.1% | 77.0% |
| Operating Income (EBIT) | ($43M) | ($63M) | ($5M) | $3M | ($5M) | ($15M) | ($24M) | ($13M) |
| Operating Margin % | -24.1% | -39.5% | -3.1% | 2.0% | -3.9% | -13.6% | -24.4% | -14.0% |
| Net Income | ($67M) | ($790M) | ($6M) | $3M | ($6M) | ($15M) | ($24M) | ($14M) |
| Net Margin % | -38.1% | -494.2% | -3.9% | 2.2% | -4.6% | -13.2% | -23.9% | -15.8% |
| EBITDA | ($11M) | ($779M) | $5M | $9M | $4M | ($4M) | ($15M) | ($4M) |
| Earnings Per Share (EPS) | $-1.06 | $-13.43 | $-0.11 | $0.05 | $-0.12 | $-0.30 | $-0.49 | $-0.30 |
| Shares Outstanding (M) | 63M | 59M | 50M | 57M | 50M | 49M | 48M | 48M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($227M) | $56M | $10M | ($71M) | ($120M) | ($133M) | ($89M) | ($39M) | $0M |
| Capital Expenditures (CapEx) | $2M | $1M | $1M | $20M | $0M | $19M | $0M | $0M | $8M |
| Free Cash Flow (FCF) | ($230M) | $55M | $9M | ($91M) | ($120M) | ($152M) | ($89M) | ($40M) | ($8M) |
| FCF Margin % | -37.2% | 10.5% | 2.8% | -48.9% | -156.3% | -793.1% | -811.8% | — | — |
| Dividends Paid | — | — | — | — | $6M | $0M | — | — | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($229M) | $6M | $40M | $12M | ($2M) | ($5M) | $4M |
| Capital Expenditures (CapEx) | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $10M |
| Free Cash Flow (FCF) | ($45M) | ($229M) | $5M | $39M | $12M | ($2M) | ($5M) | ($6M) |
| FCF Margin % | -25.6% | -143.5% | 3.7% | 29.7% | 9.3% | -1.8% | -5.1% | -6.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B | $843M | $671M | $647M | $353M | $295M | $241M | $147M | $52M |
| Cash & Cash Equivalents | $331M | $297M | $223M | $286M | $28M | $31M | $142M | $12M | $52M |
| Total Liabilities | $1.1B | $528M | $445M | $398M | $211M | $174M | $69M | $16M | $62M |
| Total Debt (Short + Long-Term) | $750M | $312M | $310M | $308M | $1M | $1M | $1M | $0M | $0M |
| Total Shareholders' Equity | ($10M) | $315M | $226M | $249M | $142M | $120M | $172M | $130M | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MIRM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms